NeOnc to present NEO100 brain cancer study data at Society for Neuro-Oncology meeting
NTHI•NeOnc Technologies plans to present NEO100 and NEO212 clinical data on Nov. 13, 2026, at the Society for Neuro-Oncology annual meeting in Philadelphia. The brief describes results in recurrent IDH1-mutant astrocytoma, recurrent glioblastoma and brain metastases.
1. Planned data presentations
NeOnc Technologies will present clinical data for NEO100 and NEO212 on Nov. 13, 2026, at the Society for Neuro-Oncology annual meeting in Philadelphia. NEO100 results describe durable tumor remission and prolonged survival in recurrent IDH1-mutant astrocytoma, based on Phase 1/2a and compassionate-use experience.
2. NEO212 results
The oral NEO212 Phase 1 data cover safety and early signs of activity in treatment-resistant recurrent glioblastoma and brain metastases.
